News | August 30, 2010

PET Infusion System Listed with Novation

August 23, 2010 — The Intego positron emission tomography (PET) infusion system is now listed with Novation LLC, one of the largest healthcare supply contracting companies in the United States. Novation is the first supply contracting company to list Intego and the first to list any automated infusion system for molecular imaging. Novation serves the purchasing needs of nearly 25,000 healthcare organizations.

Novation also secured contracts from commercial radiopharmacies to provide F18-FDG (fluorodeoxyglucose) in a multidose form, compatible with Intego. This is a significant departure from the unit-dose syringe F18-FDG distribution model, the industry standard in the United States. Multidose distribution and automated infusion using Intego creates an integrated solution for PET clinics to streamline workflow, personalize and minimize the F18-FDG dose to patients, and reduce radiation exposure to the technologist.

This first national supply contract is a milestone for Intego. "Working with Novation expands access to the Intego concept and reinforces its benefits. We believe multidose F18-FDG distribution with automated infusion is a smarter, safer, simpler way to practice PET imaging," said Doug Descalzi, executive director, Medrad Molecular Imaging. Medrad is a business of Bayer Healthcare.

Related Content

Follow up results on first multicenter trial to report outcomes of salvage low dose radiotherapy brachytherapy after external beam radiotherapy for prostate cancer
News | Prostate Cancer | October 30, 2020
October 30, 2020 — Researchers involved in the...
Evaluation of the lung apices using computed tomography angiography of the head and neck during acute ischemic stroke (AIS) can provide the first objective opportunity to screen for coronavirus disease 2019 (COVID-19)

Image courtesy of the American Heart Association

News | CT Angiography (CTA) | October 30, 2020
October 30, 2020 — ...
José Obeso, MD, PhD, (left) of of the Centro Integral de Neurociencias (HM CINAC) in Madrid and Nir Lipsman, MD, PhD, (right) of Sunnybrook Health Sciences Centre in Toronto. Each doctor is leading a clinical trial using focused ultrasound to target the striatum in patients with Parkinson's disease.

José Obeso, MD, PhD, (left) of of the Centro Integral de Neurociencias (HM CINAC) in Madrid and Nir Lipsman, MD, PhD, (right) of Sunnybrook Health Sciences Centre in Toronto. Each doctor is leading a clinical trial using focused ultrasound to target the striatum in patients with Parkinson's disease.

News | Focused Ultrasound Therapy | October 30, 2020
October 30, 2020 — A team of researchers in Madrid, Spain, and another team in Toronto, Canada, are the first in the
Interoperability between Brainlab and Accuray planning systems using Snke OS, an enterprise health tech platform
News | Treatment Planning | October 29, 2020
October 29, 2020 — Accuray Incorporated, a pioneer in the robotic stereotactic radiosurgery (...
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health S

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health System

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Card...
Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas